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that takes explicit account of the underlying MPR distribution to
understand better the nature of asthma controller medication
possession.
ALLERGY/ASTHMA—Methods and Concepts
PAA20
PHARMACOECONOMIC ANALYSIS OF A NEW CONCEPT FOR
SYMBICORT USE IN BRONCHIAL ASTHMA PATIENTS
Arkhipov VV, Chapurin S, Churilin Y
Sechenov Moscow Medical Academy, Moscow, Russia
OBJECTIVES: Pharmacoeconomics analysis of SMART
(Symbicort Maintenance and Reliever Therapy) in compare to
treatment with Seretide Multidisc and to routine therapy of
BA in Russia. METHODS: An incremental cost-effectiveness
analysis of three scenarios for BA drug therapy was done: 1)
SMART (Symbicort (Budesonide/Formoterol) 320/9 or 640/18
ìg/day + Symbicort 160/4,5 ìg/day as needed); 2) Seretide
((Fluticasone/Salmeterol) treatment (from 200/100 ìg/day to
1000/100 ìg/day) in combination with Salbutamol as needed; and
3) Routine BA therapy Comparison of SMART vs Seretide treat-
ment was based on the results of COSMOS study—randomized
study, 2143 patients with BA from 16 countries, follow-up
period 52 weeks. Routine practice was based on the results of
local pharmacoepidemiological study of outpatient treatment,
1362 patients from 20 RF regions. The study gathered informa-
tion of the type of drug therapy, health care system (HC)
resources for 1 year. Values of following ICER were compared: 1)
Difference between costs of HC resources per one additionally
invested ruble, required for a given treatment scenario 1 or 2
vs routine therapy: {HC costs (scenario) - HC costs (routine
therapy)}/{DT cost (scenario) - DT cost (routine therapy)}
DT - Drug Therapy, and 2)Difference between BA burden per
one additionally invested ruble, required for a given treatment
scenario 1 or 2 vs routine therapy: {BA burden (scenario) - BA
burden (routine therapy)}/{DT cost (scenario) - DT cost (routine
therapy)} RESULTS: Switching of patients from routine treat-
ment to SMART would reach the reduction of BA burden by 57
thousand rubles/pt/year depending on length of hospitalization
and in some regions it could be 78,000 rubles/pt/year. CONCLU-
SION: SMART in BA treatment is more preferable compared to
the routine therapy and treatment by Seretide.
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OBJECTIVES: Previous economic comparisons of montelukast
(MON) and salmeterol (SAL) used in GINA step 3 (add-on to
inhaled corticosteroids) disregard QALY measures, side-effect
costing and real-world compliance. A cost-utility model was
developed with locally imputable cost data (of drugs, asthma
attacks, and side effects, covered by the insurer). METHODS: A
large 48-week (N = 1490) randomized, double-blind trial com-
paring MON and SAL. EQ-5D quotients were derived from
AQLQ results using a multivariate model developed at ScHARR
(Shefﬁeld, UK). ANCOVA was used to calculate changes adjusted
for baseline EQ-5D. Asthma exacerbations were costed by
deﬁned categories. A side-effect model restricted to oral infec-
tions and cardiovascular events (further grouped into two and six
homogeneous cost categories, respectively) was constructed to
approximate costing of all drug-related clinical adverse experi-
ences. Adjustments of exacerbation risks and drug costs with the
relative compliance [SAL versus MON: 0.8 (range 0.5–0.9)] were
allowed to convert trial results to the real world observations.
The model was tested with costs covered by the Hungarian and
Swedish national insurance agencies. RESULTS: Among patients
with a baseline and at least one post-baseline AQLQ measure-
ment (n = 1162), there was an average increase in EQ-5D [least-
squares mean (SE)] of 0.080 (0.0054) and 0.081 (0.0054) with
MON and SAL, respectively, resulting an approximate gain of
0.056 (SE 0.0041) QALYs per patient in each group, assuming
equal compliance, over the 48 weeks. There was numerically less
exacerbations but more asthma-related hospitalizations with
SAL, and more costed side-effects (7.9% vs. 5.2%; RR = 1.52,
95% CI 1.03–2.25) compared to MON. The increased costs of
asthma attacks and side-effects with SAL were offset by the
treatment costs with MON. CONCLUSION: If efﬁcacy and costs
are adjusted for the real-world compliance, MON provides a
greater QALY-gain at an increased overall cost compared to SAL
in asthma patients inadequately controlled with inhaled corticos-
teroids alone.
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STATETRANSITION MODELS FOR ESTIMATINGTRANSITION
PROBABILITIES IN MARKOV MODELS
Campbell JD, Blough DK, Sullivan SD
University of Washington, Seattle,WA, USA
OBJECTIVES: We explore the use of state transition models
for estimating health state transition probabilities in a Markov
model. Using this approach with a longitudinal database, we
assess the Markov chain order and determine whether transition
probabilities depend on other covariates. METHODS: Markov
models rely on the Markovian assumption, i.e. the probability of
transitioning from one state to another is independent of a
patient’s prior history. Transition probabilities can considerably
impact a model’s outputs. We used current guidelines and a
longitudinal adult cohort of asthma patients to characterize their
asthma control every six months into three mutually exclusive
health states not including death: well-controlled, not well-
controlled, and very poorly controlled. We used correlated data
multinomial regression methods to ﬁt state transition models that
included lag covariates for past control status at six-month time
intervals and baseline covariates of interest. We tested the sig-
niﬁcance of ﬁrst-order (six-month lag) and second-order (six and
twelve-month lags) Markov chains and baseline covariates in
predicting six-month transition probabilities. RESULTS: We ana-
lyzed 3488 adults (average follow-up 25 months) with severe or
difﬁcult-to-treat asthma. First and second-order Markov chains,
and baseline severity all signiﬁcantly predicted present control
status (p < 0.0001 respectively). The ﬁrst-order predicted six-
month transition probability from well-controlled to well-
controlled was 0.626 (95% CI = 0.599, 0.653), but second-order
ranged from 0.362 (95% CI = 0.270, 0.467) for those that were
very poorly controlled twelve-months ago to 0.738 (95%
CI = 0.703, 0.770) for those that were well-controlled twelve-
months ago. CONCLUSION: In our example, assuming ﬁrst-
order six-month transition probabilities without regard for a
patient’s second-order (six and twelve-month past) control status
or baseline severity level was a simpliﬁcation that would likely
bias Markov model outputs. All models are simpliﬁcations but
where data are available, state transition models are tools that
can help a Markov model remain simple, but not overly so.
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